Opinion|Videos|August 7, 2024
AYA ALL: Pediatric and Adult Inspired Regimens
Focusing on the current treatment landscape for patients with AYA ALL, the panel discusses clinical practices and treatment decisions based on age.
Advertisement
Video content above is prompted by the following questions:
- What is the current treatment landscape for AYA ALL?
- How has the treatment landscape evolved over time?
- What is the role of asparaginase in the treatment of ALL in adolescents and young adults (AYA)?
- What are some challenges in treating this patient population?
- When treating AYA ALL in your practice, do you usually consider a pediatric-inspired regimen or an adult-inspired regimen?
- Have you noticed a difference in outcomes between pediatric and adult regimens?
- Have you noticed a difference in outcomes between pediatric and adult regimens?
Advertisement
Related to this article
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS.
Epcoritamab plus R-CHOP reduced the risk of progression or death by 51% vs R-CHOP alone in newly diagnosed DLBCL.
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Oral azacitidine and cedazuridine met the end point of total cycle azacitidine exposure vs subcutaneous azacitidine in MDS or CMML.
Interim data showed that the BCMA-directed CAR T-cell therapy NXC-201 generated complete responses in relapsed/refractory AL amyloidosis.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
4
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
5